Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Name: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
License: Public Domain

Bristol-Myers Squibb

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

non-small-cell-lung-cancer

non-small cell lung cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 125851
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.